NL8502017A - Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten. - Google Patents

Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten. Download PDF

Info

Publication number: NL8502017A
Authority: NL; Netherlands
Prior art keywords: inhibitor; protein; plasma; urokinase; methods
Prior art date: 1985-07-12

Application number

NL8502017A

Other languages

English (en)

Dutch (nl)

Original Assignee

Tno

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-07-12

Filing date

1985-07-12

Publication date

1987-02-02

1985-07-12 Application filed by Tno filed Critical Tno

1985-07-12 Priority to NL8502017A priority Critical patent/NL8502017A/nl

1986-07-10 Priority to AT86201213T priority patent/ATE57471T1/de

1986-07-10 Priority to EP86201213A priority patent/EP0208383B1/de

1986-07-10 Priority to DE8686201213T priority patent/DE3674955D1/de

1986-07-11 Priority to US06/884,418 priority patent/US5004802A/en

1986-07-12 Priority to JP61164544A priority patent/JP2512437B2/ja

1987-02-02 Publication of NL8502017A publication Critical patent/NL8502017A/nl

Links

238000000034 method Methods 0.000 title claims abstract description 32
102000004169 proteins and genes Human genes 0.000 title claims abstract description 30
108090000623 proteins and genes Proteins 0.000 title claims abstract description 30
239000003112 inhibitor Substances 0.000 title claims description 100
239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
230000008569 process Effects 0.000 title claims description 5
238000004519 manufacturing process Methods 0.000 title 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims abstract description 24
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims abstract description 24
229960005356 urokinase Drugs 0.000 claims abstract description 24
102000001938 Plasminogen Activators Human genes 0.000 claims abstract description 17
108010001014 Plasminogen Activators Proteins 0.000 claims abstract description 17
229940127126 plasminogen activator Drugs 0.000 claims abstract description 17
229920000936 Agarose Polymers 0.000 claims abstract description 6
102000023732 binding proteins Human genes 0.000 claims abstract description 5
108091008324 binding proteins Proteins 0.000 claims abstract description 5
238000005227 gel permeation chromatography Methods 0.000 claims abstract description 3
230000002779 inactivation Effects 0.000 claims description 11
210000004369 blood Anatomy 0.000 claims description 9
239000008280 blood Substances 0.000 claims description 9
239000012190 activator Substances 0.000 claims description 7
102100033571 Tissue-type plasminogen activator Human genes 0.000 claims description 5
238000001042 affinity chromatography Methods 0.000 claims description 4
102000006395 Globulins Human genes 0.000 claims description 3
108010044091 Globulins Proteins 0.000 claims description 3
239000006143 cell culture medium Substances 0.000 claims description 3
108050006955 Tissue-type plasminogen activator Proteins 0.000 claims 4
238000002955 isolation Methods 0.000 claims 2
230000000415 inactivating effect Effects 0.000 claims 1
238000006386 neutralization reaction Methods 0.000 claims 1
230000002441 reversible effect Effects 0.000 abstract description 9
238000002560 therapeutic procedure Methods 0.000 abstract description 3
102000004506 Blood Proteins Human genes 0.000 abstract description 2
108010017384 Blood Proteins Proteins 0.000 abstract description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 abstract description 2
102000006734 Beta-Globulins Human genes 0.000 abstract 1
108010087504 Beta-Globulins Proteins 0.000 abstract 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
210000002381 plasma Anatomy 0.000 description 64
230000000694 effects Effects 0.000 description 45
230000005764 inhibitory process Effects 0.000 description 38
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 18
108010073385 Fibrin Proteins 0.000 description 16
102000009123 Fibrin Human genes 0.000 description 16
229950003499 fibrin Drugs 0.000 description 16
238000011534 incubation Methods 0.000 description 13
238000005259 measurement Methods 0.000 description 13
102000013566 Plasminogen Human genes 0.000 description 11
108010051456 Plasminogen Proteins 0.000 description 11
230000003993 interaction Effects 0.000 description 10
241000700159 Rattus Species 0.000 description 8
210000002889 endothelial cell Anatomy 0.000 description 8
238000002523 gelfiltration Methods 0.000 description 8
238000003556 assay Methods 0.000 description 7
108010049003 Fibrinogen Proteins 0.000 description 6
102000008946 Fibrinogen Human genes 0.000 description 6
229940012952 fibrinogen Drugs 0.000 description 6
238000000691 measurement method Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
230000009471 action Effects 0.000 description 5
230000033228 biological regulation Effects 0.000 description 5
230000020764 fibrinolysis Effects 0.000 description 5
238000001802 infusion Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
229940012957 plasmin Drugs 0.000 description 4
108010073863 saruplase Proteins 0.000 description 4
230000002537 thrombolytic effect Effects 0.000 description 4
206010048998 Acute phase reaction Diseases 0.000 description 3
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
108010023197 Streptokinase Proteins 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000035602 clotting Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 3
229960004281 desmopressin Drugs 0.000 description 3
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
238000011533 pre-incubation Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
229960005202 streptokinase Drugs 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
102000016359 Fibronectins Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
102000018997 Growth Hormone Human genes 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108010007544 Protease Nexins Proteins 0.000 description 2
102000007324 Protease Nexins Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000004658 acute-phase response Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000013213 extrapolation Methods 0.000 description 2
108010073651 fibrinmonomer Proteins 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000001155 isoelectric focusing Methods 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
238000004448 titration Methods 0.000 description 2
102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
108091028026 C-DNA Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108010044316 Cohn fraction III Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101000872147 Homo sapiens Biogenesis of lysosome-related organelles complex 1 subunit 6 Proteins 0.000 description 1
101000693011 Homo sapiens Pancreatic alpha-amylase Proteins 0.000 description 1
101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
208000004221 Multiple Trauma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000005686 Serum Globulins Human genes 0.000 description 1
108010045362 Serum Globulins Proteins 0.000 description 1
102100024554 Tetranectin Human genes 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000011138 biotechnological process Methods 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
150000001993 dienes Chemical class 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
102000056984 human BLOC1S6 Human genes 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000000937 inactivator Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000008188 pellet Substances 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
108010088880 plasmagel Proteins 0.000 description 1
239000002806 plasmin inhibitor Substances 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000018338 positive regulation of fibrinolysis Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
235000008001 rakum palm Nutrition 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000010405 reoxidation reaction Methods 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
108010013645 tetranectin Proteins 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8132—Plasminogen activator inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NL8502017A 1985-07-12 1985-07-12 Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten. NL8502017A (nl)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
NL8502017A NL8502017A (nl)	1985-07-12	1985-07-12	Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten.
AT86201213T ATE57471T1 (de)	1985-07-12	1986-07-10	Im blut identifiziertes protein, ein verfahren zu seiner zubereitung, ein verfahren fuer die bestimmung dieses proteins und ebenfalls des t-pa-hemmungsfaktors und pharmazeutische zusammensetzungen, die dieses protein enthalten.
EP86201213A EP0208383B1 (de)	1985-07-12	1986-07-10	Im Blut identifiziertes Protein, ein Verfahren zu seiner Zubereitung, ein Verfahren für die Bestimmung dieses Proteins und ebenfalls des t-PA-Hemmungsfaktors und pharmazeutische Zusammensetzungen, die dieses Protein enthalten
DE8686201213T DE3674955D1 (de)	1985-07-12	1986-07-10	Im blut identifiziertes protein, ein verfahren zu seiner zubereitung, ein verfahren fuer die bestimmung dieses proteins und ebenfalls des t-pa-hemmungsfaktors und pharmazeutische zusammensetzungen, die dieses protein enthalten.
US06/884,418 US5004802A (en)	1985-07-12	1986-07-11	100KDa protein from blood which binds to and inhibits the activity of plasminogen activators
JP61164544A JP2512437B2 (ja)	1985-07-12	1986-07-12	血液蛋白質、その調製方法、前記蛋白質およびｔ−ＰＡ阻害剤をアツセイする方法、および前記蛋白質を含有する製薬学的組成物

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL8502017		1985-07-12
NL8502017A NL8502017A (nl)	1985-07-12	1985-07-12	Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten.

Publications (1)

Publication Number	Publication Date
NL8502017A true NL8502017A (nl)	1987-02-02

Family

ID=19846293

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8502017A NL8502017A (nl)	1985-07-12	1985-07-12	Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten.

Country Status (6)

Country	Link
US (1)	US5004802A (de)
EP (1)	EP0208383B1 (de)
JP (1)	JP2512437B2 (de)
AT (1)	ATE57471T1 (de)
DE (1)	DE3674955D1 (de)
NL (1)	NL8502017A (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5372719A (en) *	1992-03-30	1994-12-13	Perseptive Biosystems, Inc.	Molecular imaging
US5474766A (en) *	1992-12-18	1995-12-12	Washington University	Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
US5607841A (en) *	1994-06-20	1997-03-04	Lipinski; Boguslaw	Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
US10160813B2 (en)	2013-01-22	2018-12-25	University Of Tennessee Research Foundation	Tissue plasminogen activator antibodies and methods of use

1985
- 1985-07-12 NL NL8502017A patent/NL8502017A/nl not_active Application Discontinuation
1986
- 1986-07-10 DE DE8686201213T patent/DE3674955D1/de not_active Expired - Fee Related
- 1986-07-10 AT AT86201213T patent/ATE57471T1/de not_active IP Right Cessation
- 1986-07-10 EP EP86201213A patent/EP0208383B1/de not_active Expired - Lifetime
- 1986-07-11 US US06/884,418 patent/US5004802A/en not_active Expired - Fee Related
- 1986-07-12 JP JP61164544A patent/JP2512437B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5004802A (en)	1991-04-02
JP2512437B2 (ja)	1996-07-03
DE3674955D1 (de)	1990-11-22
EP0208383B1 (de)	1990-10-17
ATE57471T1 (de)	1990-11-15
EP0208383A1 (de)	1987-01-14
JPS6277326A (ja)	1987-04-09

Legal Events

Date	Code	Title	Description
1987-02-02	A1B	A search report has been drawn up
1988-03-01	BV	The patent application has lapsed

Publication	Publication Date	Title
Aoki et al.	1977	The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
Hackeng et al.	1994	Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa.
Williams et al.	1992	A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein.
Lijnen et al.	1983	Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
Colucci et al.	1985	Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.
Levin	1986	Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells
Debrock et al.	1997	Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms
Robbie et al.	1993	The roles of α2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis
Mutch et al.	2003	Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI
Larrieu et al.	1972	Comparative effects of fibrinogen degradation fragments D and E on coagulation
Collen et al.	1982	In vivo studies of a synthetic inhibitor of thrombin
JP2008289498A (ja)	2008-12-04	精製されたマルチメラ−ゼ
Edelberg et al.	1991	The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein (a).
Patston et al.	1990	Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems.
Kowalski et al.	1965	Circulating fibrinogen degradation products (FDP) in dog blood after intravenous thrombin infusion
Loskutoff et al.	1986	Fibrinolytic system of cultured endothelial cells: regulation by plasminogen activator inhibitor
Lijnen et al.	1983	Interaction of heparin with histidine-rich glycoprotein and with antithrombin III
Mattsson et al.	2001	Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro
Marlar et al.	1993	Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma
Raja et al.	2003	Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis
Henderson et al.	1969	The Mechanism of Enhanced Streptokinase‐Induced Clot Lysis following In‐vitro Factor‐XIII Inactivation
NL8502017A (nl)	1987-02-02	Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten.
Abildgaard	1969	Inhibition of the thrombin-fibrinogen reaction by α2-macroglobulin, studied by N-terminal analysis
Alkjaersig et al.	1983	Formation of soluble fibrin oligomers in purified systems and in plasma
Serón et al.	2010	Thrombin‐activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis